thiodigalactoside has been researched along with Lung Neoplasms in 2 studies
*Lung Neoplasms: Tumors or cancer of the LUNG. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cumpstey, I; Delaine, T; Ingrassia, L; Kiss, R; Le Mercier, M; Leffler, H; Nilsson, UJ; Okechukwu, P | 1 |
| Bratman, SV; Chan, C; Diehn, M; Giaccia, AJ; Gupta, A; Koong, AC; Kuo, P; Le, QT; Loo, BW; Say, C; Shultz, DB; von Eyben, R; Wang, Z | 1 |
2 other study(ies) available for thiodigalactoside and Lung Neoplasms
| Article | Year |
|---|---|
Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells.
Topics: Cell Line, Tumor; Cell Movement; Drug Design; Drug Screening Assays, Antitumor; Esters; Galectins; Humans; Inhibitory Concentration 50; Kinetics; Lung Neoplasms; Male; Models, Chemical; Prostatic Neoplasms; Protein Structure, Tertiary; Thiogalactosides | 2008 |
Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response.
Topics: Animals; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Galectin 1; Humans; Lung Neoplasms; Lymphopenia; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Thiogalactosides | 2014 |